Recce Pharmaceuticals Sponsored Session: New Frontiers in Sepsis and Urosepsis Treatment: Synthetic Anti-Infectives to Combat Superbugs
Includes a Live Web Event on 09/25/2024 at 8:30 AM (PDT)
Description:
Date/Time: September 25, 2024 | 11:30 am - 12:00 pm ET
Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is developing a New Class of Synthetic Anti-Infectives designed to address the urgent global health threat posed by antibiotic-resistant superbugs and emerging viral pathogens. With no new class of antibiotics in over 30 years, a novel class of medication that can tackle multidrug-resistant bacteria and does not increase antibiotic resistance is essential to tackle the constant infective threat. In this sponsored session, learn about Recce’s synthetic anti-infective compound, RECCE® 327 (R327), which has demonstrated bactericidal activity against all ESKAPEE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter spp., and Escherichia coli) without contributing to resistance. With a unique mechanism of action, the compound has the ability to continuously kill multidrug-resistant superbugs. Discover how Recce Pharmaceuticals Ltd is revolutionizing the fight against sepsis, urosepsis, and more with their innovative class of synthetic anti-infectives. With successful outcomes in Phase I/II trials and preparations for Phase III in Indonesia, Recce's RECCE® 327 shows significant promise against antibiotic-resistant superbugs.
Target Audience:
Nurses, advanced practice providers, physicians, emergency responders, pharmacists, medical technologists, respiratory therapists, physical/occupational therapists, infection prevention specialists, data/quality specialists, and more.
James Graham
Managing Director & Chief Executive Officer
Recce Pharmaceuticals
James Graham is the Chief Executive Officer of Recce Pharmaceuticals. He was formerly Executive Director and has extensive experience in marketing, business development, and commercialization of early-stage technologies with global potential. Mr. Graham serves on Recce’s Board of Directors and has invested in almost every capital raise to date with a focus on expanding Recce’s commercial opportunities and clinical initiatives.